Ram Vasudevan Nampoothiri

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that supports the findings of this study are available in the material of this article. Supporting Information Filename Description ejh70081-sup-0001-TableS1.docxWord 2007 document , 15.8 KB Table S1: Distribution of covariates of interest by Response to EPAG.

Ranging in severity from readily curable to aggressive and rapidly fatal, acute myeloid leukemia (AML) is a heterogeneous malignancy. These outcomes are governed by its underlying genomic landscape. A comprehensive understanding of the cytogenetic and molecular abnormalities that drive leukemogenesis is paramount to selecting optimal treatment strategies. AML harboring t(8;21)(q22;q22,1) and inv(16)(q13.1;q22) is collectively referred to as core binding factor AML (CBF-AML).

ORIGINAL ARTICLE Ram Vasudevan Nampoothiri, Ram Vasudevan Nampoothiri Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Center, University of Toronto, Toronto Search for more papers by this author Ivan Pasic, Ivan Pasic orcid.org/0000-0001-7595-0113 Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Center, University of Toronto, Toronto Search for more papers by this author Arjun Datt Law, Arjun Datt Law Hans...